X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: XFOR) | Delayed: 3.35 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.35 | 52 Week High | $ | |||
| Open | $3.40 | 52 Week Low | $ | |||
| Day High | $3.47 | P/E | N/A | |||
| Day Low | $3.26 | EPS | $ | |||
| Volume | 521,962 | |||||
